Genetix Biotherapeutics Inc.

6 trials 2 recruiting Commercial sponsor Merged from 2 name variants

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

3 Completed trials

7 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase I (Other)

Phase III: 3 Phase I (Other): 3

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Adrenoleukodystrophy 1 Sickle cell disease 1

Top IMPs

BETIBEGLOGENE AUTOTEMCEL 1 ELIVALDOGENE AUTOTEMCEL 1 LOVOTIBEGLOGENE AUTOTEMCEL 1

All trials

6 total

A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123… Pending

2024-520258-39-00 Phase I (Other) 1 country
Oncolytic virus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in the treatment of melanoma Recruiting

2024-514092-18-00 Phase I (Other) 1 country
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transdu… Recruiting

2024-513901-30-00 Phase III 1 country LOVOTIBEGLOGENE AUTOTEMCEL
Longterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Ended

2024-513904-33-00 Phase III 4 countries ELIVALDOGENE AUTOTEMCEL
Long-Term Follow-up of Subjects With Transfusion-Dependant β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic St… Ended

2024-513905-29-00 Phase III 4 countries BETIBEGLOGENE AUTOTEMCEL
A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 i… Ended

2024-518088-37-01 Phase I (Other) 1 country

Showing 1–6 of 6 trials

← All sponsors A–Z